Company & Sponsor Intelligence
Kyowa Kirin Co., Ltd.
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed3
Countries3
Therapeutic footprint
alzheimersparkinsons
Indexed studies
NCT00455507A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
parkinsons · JapanPHASE2
parkinsons · JapanPHASE2
NCT02610231Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
parkinsons · United StatesPHASE3
parkinsons · United StatesPHASE3
NCT02127476A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease
alzheimers · BelgiumPHASE1
alzheimers · BelgiumPHASE1
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →